In short
Diagnosing acute leukaemia requires a combination of blood tests, bone marrow examinations, and imaging studies to identify abnormal blood cells and determine the specific type of disease, guiding treatment decisions and helping doctors understand how the condition may respond to therapy.
Key points
- Acute leukaemia diagnosis typically begins with blood tests that can reveal abnormal blood cell counts and the presence of immature blast cells circulating in the blood.
- Bone marrow examination is essential for confirming acute leukaemia and provides crucial information about the genetic features of the disease that guide treatment decisions.
- The diagnostic process happens quickly because acute leukaemia develops rapidly and requires prompt treatment—often within days of initial symptoms.
- Genetic and molecular testing reveals dozens of possible variations in leukaemia cells, each providing clues about how aggressive the disease may be and which treatments might work best.
- Clinical trials may require additional diagnostic tests including minimal residual disease testing, which can detect extremely small numbers of remaining leukaemia cells invisible to standard tests.
- Children with acute lymphocytic leukaemia have much better survival rates than adults, with modern treatments offering a good chance for cure in young patients.
- Unlike many other cancers, acute leukaemia doesn't form solid tumors, so imaging tests play a supporting role rather than being the primary diagnostic tool.
- Understanding your specific leukaemia subtype and risk group helps doctors personalize your treatment and provides more accurate information about your individual prognosis.
Introduction: Who Should Undergo Diagnostics
People who experience persistent symptoms that don't improve as expected should consider seeking medical evaluation for acute leukaemia. The signs that warrant attention include ongoing fatigue, frequent infections that won't go away, unusual bleeding or bruising, fever without an obvious cause, and night sweats that disrupt sleep. Many of these symptoms can feel like a cold or flu at first, but unlike typical viral illnesses, they don't get better with time and may actually worsen.
Because acute leukaemia develops quickly and aggressively, early diagnosis is essential. The disease progresses rapidly, creating immature blood cells instead of healthy ones, which means symptoms can appear suddenly and become more noticeable within weeks. If you notice that you're feeling increasingly unwell, looking pale or "washed out," experiencing shortness of breath, or developing swollen lumps in your neck, armpits, abdomen or groin, it's important to make an appointment with your doctor promptly.
Adults over the age of 75 are at higher risk for acute leukaemia, though the disease can affect younger adults and children as well. Children with acute leukaemia may show signs of bone pain, weakness, loss of appetite, or unexplained weight loss in addition to the more common symptoms. Because acute leukaemia doesn't wait, and because it's the most common type of cancer in children, parents should not hesitate to seek medical advice if their child shows persistent concerning symptoms.
Some people arrive at the emergency department rather than a doctor's office, particularly when symptoms become severe or frightening. This might happen if someone experiences severe bleeding that won't stop, extremely high fever, or intense weakness that makes daily activities impossible. Either route—through a family doctor or emergency department—can lead to appropriate diagnostic testing.
Diagnostic Methods for Identifying Acute Leukaemia
Blood Tests
The diagnostic journey for acute leukaemia typically begins with blood tests, which are often the first indication that something is wrong. During a blood test, a healthcare professional draws a sample of blood from a vein, usually in your arm, and sends it to a laboratory for analysis. These tests can reveal abnormal numbers of blood cells—too many or too few white blood cells, not enough red blood cells, and insufficient platelets. The blood test may also show the presence of blast cells, which are immature cells that normally stay in the bone marrow but appear in the blood when leukaemia is present.
Blood tests alone cannot provide a complete diagnosis, but they serve as a crucial screening tool. If your doctor sees concerning results, they will refer you urgently to a specialist called a haematologist, who focuses on blood conditions and diseases. This referral happens quickly because acute leukaemia requires prompt attention. The haematologist will order additional, more detailed tests to confirm the diagnosis and understand exactly what type of leukaemia is present.
Bone Marrow Examination
The most definitive test for diagnosing acute leukaemia is a bone marrow examination, which includes two procedures often done at the same time: bone marrow aspiration and bone marrow biopsy. During bone marrow aspiration, a healthcare professional uses a thin needle to remove a small amount of liquid bone marrow, usually from a spot in the back of your hip bone, also called the pelvis. In a bone marrow biopsy, a small piece of bone tissue along with the enclosed marrow is removed using a slightly larger needle.
These samples are sent to a laboratory where specialists examine them under a microscope. The doctors look for the percentage of blast cells in the bone marrow. In acute leukaemia, more than a certain threshold of cells in the bone marrow are immature blast cells, which confirms the diagnosis. The examination also helps doctors classify the blood cells into specific types based on their size, shape, and other features. This classification is important because different types of acute leukaemia behave differently and respond to different treatments.
Laboratory specialists also examine the cells for changes in chromosomes and look for mutations in certain genes. Chromosomes are structures inside cells that contain genetic material, and when they change or mutate, they can cause cells to behave abnormally. These genetic and molecular features help doctors determine whether the leukaemia cells began from B lymphocytes or T lymphocytes, which are different types of white blood cells. Understanding these details allows your doctor to develop a treatment plan tailored to your specific situation.
Lumbar Puncture
After acute leukaemia has been diagnosed, doctors need to know whether the cancer has spread to the central nervous system, which includes the brain and spinal cord. To check this, they may perform a lumbar puncture, also known as a spinal tap. During this procedure, you typically lie on your side with your knees drawn up to your chest. A needle is inserted into the spinal canal in your lower back to collect cerebrospinal fluid, the liquid that surrounds the brain and spinal cord. This fluid is tested for the presence of leukaemia cells.
Knowing whether leukaemia has reached the central nervous system is important because it affects treatment decisions. If leukaemia cells are found in the cerebrospinal fluid, additional therapy targeting the central nervous system may be needed. This might include medication delivered directly into the spinal fluid or radiation therapy to the brain and spinal cord.
Imaging Tests
Unlike many other cancers, acute leukaemia doesn't generally form solid masses or tumors that show up easily on imaging tests. However, doctors may still order imaging studies such as X-rays, computed tomography (CT) scans, or ultrasounds to check whether the disease has affected other parts of the body. These tests can reveal whether leukaemia has spread to organs like the liver, spleen, or lymph nodes, or whether it has affected the testicles in males.
A chest X-ray might be ordered to look for enlarged lymph nodes in the chest or to check for signs of infection in the lungs, which can be more common in people with leukaemia because their immune system isn't working properly. CT scans provide more detailed, three-dimensional images and can help doctors see the size and condition of internal organs and lymph nodes throughout the body.
Classification Systems
Once acute leukaemia is confirmed, doctors use classification systems to categorize the disease into subtypes. One widely used system is the World Health Organization (WHO) classification, which divides leukaemia based on the type of blood cells affected and the genetic changes present in those cells. For acute myeloid leukaemia, there are several subtypes including myeloid leukaemia, acute monocytic leukaemia, acute megakaryocytic leukaemia, and acute promyelocytic leukaemia. Each subtype behaves differently and requires different treatment approaches.
Doctors also assign acute leukaemia to risk groups based on genetic changes and other factors found during diagnosis. These risk groups help predict how well the disease will respond to treatment and guide decisions about which treatments to use. Some patients are classified as having a high risk of the disease coming back after treatment, while others may have more favorable genetic features that suggest a better response to standard therapy.
Diagnostics for Clinical Trial Qualification
When doctors consider enrolling patients in clinical trials for acute leukaemia, additional diagnostic criteria come into play. Clinical trials often have specific requirements about the type and stage of disease, the genetic characteristics of the leukaemia cells, and the patient's overall health status. These requirements ensure that the trial studies the treatment in the right group of patients and that participants are likely to be safe during the study.
One important diagnostic marker used in clinical trials is minimal residual disease (MRD). This refers to a very small number of leukaemia cells that remain in the bone marrow but can only be detected using highly sensitive tests like flow cytometry or polymerase chain reaction (PCR). Standard tests, such as looking at cells under a microscope, cannot see these remaining cells. Clinical trials may use MRD testing to determine which patients should receive additional treatment or to measure how well a new therapy is working.
Genetic and molecular testing plays a particularly important role in clinical trial eligibility. Recent guidelines from the European LeukemiaNet (ELN) emphasize the importance of molecular characterization and risk stratification for people with acute myeloid leukaemia. Clinical trials may specifically seek patients with certain gene mutations or chromosome changes because some experimental treatments are designed to target these specific abnormalities. For example, some trials may only accept patients whose leukaemia cells have particular genetic markers that the study drug is designed to affect.
Complete blood counts and bone marrow examinations must typically show a certain percentage of blast cells for someone to qualify for a clinical trial studying acute leukaemia. Trials studying newly diagnosed disease might require that patients have more than a specific percentage of blasts in their bone marrow, confirming active disease that hasn't been treated yet. Conversely, trials for patients in remission may require that blast counts be below a certain level, demonstrating that initial treatment has worked.
Assessment of overall health is also part of clinical trial qualification. Doctors use various tests to measure how well different organs are functioning, including the heart, liver, and kidneys. This might involve blood tests to check liver and kidney function, an electrocardiogram (ECG) to assess heart rhythm and function, or imaging tests. These assessments help ensure that patients can safely tolerate the experimental treatment being studied in the trial.
Age and previous treatment history are additional factors that affect clinical trial eligibility. Some trials focus specifically on older adults or on younger patients. Others may require that participants have not received any prior treatment for their leukaemia, while some trials specifically study treatments for disease that has returned after initial therapy or hasn't responded to standard treatments. Diagnostic tests must confirm the patient's treatment history and current disease status to determine if they meet these criteria.
Prognosis and Survival Rate
Prognosis
The outlook for people with acute leukaemia depends on several important factors that doctors identify during the diagnostic process. Age plays a significant role—acute lymphocytic leukaemia is the most common type of cancer in children, and treatments offer a good chance for a cure in young patients. However, for adults, particularly those over 75 years old, the chance of a cure is greatly reduced and the prognosis is less favorable.
Genetic and molecular characteristics found in the leukaemia cells strongly influence prognosis. Some patients have genetic changes that indicate their disease will respond well to treatment, while others have features that suggest the leukaemia may be more difficult to control. The specific subtype of acute leukaemia also matters—for instance, acute promyelocytic leukaemia has a different outlook compared to other forms of acute myeloid leukaemia. Risk groups based on these genetic factors help doctors predict whether the disease is likely to go into remission and whether it might come back after treatment.
How well the leukaemia responds to initial treatment is another key factor affecting prognosis. Doctors assess response by measuring whether the disease reaches complete remission, meaning that blood cell counts return to normal levels and less than 5% of cells in the bone marrow are blast cells. Patients who achieve complete remission with initial chemotherapy generally have a better outlook. Some patients may have minimal residual disease, where very small numbers of leukaemia cells remain but can only be detected with sensitive tests. The presence or absence of these remaining cells helps doctors understand the risk of the disease returning.
Overall health status and other medical conditions also affect prognosis. Patients who are otherwise healthy and able to tolerate intensive treatment may have better outcomes than those with other serious health problems. Previous exposure to chemotherapy or radiation for other cancers can increase the risk of developing acute leukaemia and may also affect how well the new leukaemia responds to treatment.
The unpredictable nature of acute leukaemia means that the disease trajectory can be difficult to predict. Unlike some cancers that progress slowly, acute leukaemia develops rapidly and requires immediate treatment. Even with treatment, the course can be uncertain, with some patients experiencing prolonged remission while others may see their disease return. This unpredictability makes prognosis discussions important but sometimes challenging for patients and their families.
Survival Rate
Survival statistics for acute leukaemia vary significantly depending on the type of leukaemia and the patient's age. For adults aged 20 and older with acute myeloid leukaemia, the five-year survival rate is approximately 27%. This means that about 27 out of 100 adults with this disease are alive five years after diagnosis. These statistics represent averages across all patients and all types of acute myeloid leukaemia, and individual outcomes can vary considerably based on the factors mentioned above.
Children with acute lymphocytic leukaemia have notably better survival rates compared to adults with the same disease. Modern treatments result in a good chance for cure in pediatric patients, with survival rates much higher than those seen in adults. This difference reflects both the biology of the disease in children versus adults and how well young patients tolerate intensive treatments.
Despite advances in treatment approaches, acute myeloid leukaemia remains a disease with challenging outcomes, especially in older populations. Newer treatments are helping people live longer with acute myeloid leukaemia, and ongoing research continues to improve survival rates. However, the prognosis remains less favorable compared to many other types of cancer, highlighting the importance of continued research and development of new therapies.
It's important to remember that survival statistics are based on large groups of people and represent outcomes from past years. Individual results can differ significantly from these averages. Some patients do much better than statistics would predict, while others face greater challenges. Your doctor can provide more personalized information about prognosis based on your specific situation, including your age, overall health, the genetic features of your leukaemia, and how well your disease responds to initial treatment.
